The researchers engineered a fusion protein combining IL-15 and IL-15Rα (designated OV-IL15C), which was expressed within gliomas and demonstrated the ability to enhance cytotoxicity against glioblastoma (GBM) both in vivo and in vitro, while also improving the survival of NK and CD8+ T cells (31). Here, CD8A is linked to glioblastoma.